May 14, 2025, 08:49

Cancer Grand Challenge: Rewiring Cancer Cells

This challenge aims to pioneer novel approaches that rewire the internal signalling systems of cancer cells to reduce malignancy or induce self-destruction. By harnessing advances in synthetic biology and systems biology, teams will explore ways to shift cancer cell behavior away from oncogenesis, creating new therapeutic strategies that avoid common resistance mechanisms seen with targeted inhibitors.

Eligibility Criteria:

Open to global, interdisciplinary research teams
Must combine expertise in areas such as synthetic biology, AI, medicinal chemistry, structure-based drug design, cancer biology, immunology, and cellular signalling
Proposals must not focus on targeted protein degradation

Funding Details:

Up to £20 million (USD 25 million) per team
Duration: Not specified

Deadline:

Expressions of Interest due: 18 June 2025

More Information:

Submit your Expression of Interest

cancer Cancer Cell Signalling Cancer Grand Challenge cancer therapy cancer treatment innovation cell phenotype modulation immunogenic cell death OncoDaily oncogenic signalling Oncology rewiring cancer Synthetic Biology tumour heterogeneity

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot